Shares of Senseonics Holdings (NYSEMKT: SENS) rose by nearly 10% by the end of trading Thursday afternoon this week, according to data from S&P Global Market Intelligence. Senseonics is a small-cap player in the high-value and ultra-high growth continuous glucose monitoring (CGM) system market. Senseonics applied for a premarket approval to the U.S. Food and Drug Administration to extend the wearable life of the Eversense CGM system to 180 days on Sept. 30.
GERMANTOWN, Md., October 04, 2021--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the "Plan") in accordance with NYSE American Company Guide Section 711(a).
Investors need to pay close attention to Senseonics (SENS) stock based on the movements in the options market lately.